Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent IMRT and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid Cancer
NCT03975231Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Sep 2020
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dabrafenib + trametinib and trametinib in anaplastic thyroid cancer (ATC), sponsored by City of Hope. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Sep 2020; status: suspended.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT03975231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975231.